Catalyst
Slingshot members are tracking this event:
Infinity Pharma (INFI) to present Phase 2 updated data of eganelisib (IPI-549) in combination with Tecentriq and Abraxane, in triple negative breast cancer cohort of MARIO-3 on July 27, 2021
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| INFI |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 27, 2021
Occurred Source:
https://investors.infi.com/news-releases/news-release-details/infinity-pharmaceuticals-presents-updated-data-phase-2-mario-275
Related Projects
- Discussing Infinity Pharma’s Eganelisib in anticipation of Updated TNBC data from MARIO-3 INFI Executed On: Jul 26, 2021 at 06:00 PM EDT
Related Keywords
Eganelisib, Tecentriq, Abraxane
